Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at HC Wainwright issued their Q1 2027 EPS estimates for Sutro Biopharma in a report released on Friday, November 13th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($1.97) per share for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($8.12) per share. HC Wainwright also issued estimates for Sutro Biopharma's Q2 2027 earnings at ($2.18) EPS.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.64) by ($0.26). The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $14.11 million.
STRO has been the subject of a number of other research reports. Wall Street Zen upgraded Sutro Biopharma from a "strong sell" rating to a "sell" rating in a research note on Monday. Stifel Nicolaus set a $48.00 target price on Sutro Biopharma and gave the company a "buy" rating in a research report on Friday, August 7th. Wedbush reiterated an "outperform" rating and set a $60.00 target price on shares of Sutro Biopharma in a research note on Thursday, October 15th. Mizuho raised shares of Sutro Biopharma to a "strong-buy" rating in a report on Wednesday, September 16th. Finally, Barclays boosted their price target on shares of Sutro Biopharma from $56.00 to $57.00 and gave the stock an "overweight" rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $49.60.
View Our Latest Analysis on STRO
Sutro Biopharma Price Performance
Sutro Biopharma stock opened at $9.82 on Monday. Sutro Biopharma has a 52 week low of $7.15 and a 52 week high of $43.85. The company's 50 day moving average price is $13.18 and its two-hundred day moving average price is $22.54. The stock has a market cap of $162.82 million, a P/E ratio of -0.82 and a beta of 1.56.
Hedge Funds Weigh In On Sutro Biopharma
Institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC bought a new stake in Sutro Biopharma in the 1st quarter valued at about $19,956,000. Perceptive Advisors LLC bought a new position in Sutro Biopharma during the first quarter worth about $17,818,000. ADAR1 Capital Management LLC boosted its position in Sutro Biopharma by 681.8% during the first quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company's stock worth $13,064,000 after purchasing an additional 457,364 shares during the period. Affinity Asset Advisors LLC boosted its position in Sutro Biopharma by 42.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company's stock worth $26,642,000 after purchasing an additional 321,137 shares during the period. Finally, Merck & Co. Inc. bought a new position in Sutro Biopharma during the second quarter worth about $9,042,053. Hedge funds and other institutional investors own 96.99% of the company's stock.
Sutro Biopharma Company Profile
(
Get Free Report)
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro's clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.